Abstracts tagged "drug treatment"

Abstract Number: 1974 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Pregabalin for Fibromyalgia in a Population of Chinese Patients: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
Xiao Zhang¹, Huji Xu², Zhiyi Zhang³, Yang Li⁴, Lynne Pauer⁵, Shanmei Liao⁶, Gaiping Xu⁷ and Fengchun Zhang⁸, ¹Guangdong General Hospital, Guangdong, China, Guangdong, China, ²Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China, ³The First Affiliated Hospital of Harbin Medical University, Harbin, China, Harbin, China, ⁴The Second Affiliated Hospital of Harbin Medical University, Harbin, China, Harbin, China, ⁵Pfizer, Groton, CT, USA, Groton, CT, ⁶Pfizer (China) Statistics Department, Global Innovative Pharma Business, Shanghai, China, Shanghai, China, ⁷Pfizer (China) Clinical Development, Global Innovative Pharma Business, Beijing, China, Beijing, China, ⁸Peking Union Medical College Hospital, Beijing, China
Background/Purpose: Global trial data demonstrate the efficacy of pregabalin for the treatment of pain associated with fibromyalgia (FM), but there are currently no approved medical…
Abstract Number: 2493 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Tofacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Prior Therapies
John Tesser¹, Ahmet Gül², Ewa Olech³, Kurt Oelke⁴, Tatjana Lukic⁵, Christopher W Murray⁶, Chuanbo Zang⁶ and Liza Takiya⁶, ¹Arizona Arthritis & Rheumatology Associates, Glendale, AZ, ²Istanbul University, Istanbul, Turkey, ³UNLV School of Medicine, Las Vegas, NV, ⁴Rheumatic Disease Center, Glendale, WI, ⁵Pfizer Inc, New York, NY, ⁶Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Patients (pts) with RA generally receive conventional synthetic DMARDS (csDMARDs)…
Abstract Number: 1442 • 2016 ACR/ARHP Annual Meeting
Suppression of Acute Arthritis By N-Methyl-3,4-Dichloropropionaniline (N-MeDCPA), a Reversible Orai Calcium Channel Inhibitor
John Barnett¹, Lisa Robinson², Jonathan Soboloff³, Rosana Schafer⁴, Ida Holaskova⁵, Meenal Elliott¹, Michelle Witt², Raphael Hirsch⁶ and Harry Blair⁷, ¹Microbiology, Immunology and Cell Biology, West Virginia University, Morgantown, WV, ²Pathology, West Virginia University, Morgantown, WV, ³Dept of Medical Genetics and Molecular Biochemistry, Temple University, Philadelphia, PA, ⁴Dept Micro, Immun & Cell Biol, West Virginia University, Morgantown, WV, ⁵West Virginia University, Morgantown, WV, ⁶Stead Family Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA, ⁷pathology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Bone maintenance is a balance between the removal of old bone by osteoclasts (OCL) and the production of new bone by osteoblasts. In the…
Abstract Number: 1552 • 2016 ACR/ARHP Annual Meeting
The Association of Fatigue, Comorbidities and Anti Rheumatic Drugs in Rheumatoid Arthritis: Results from French Cohort Study of Comorbidities
Anne Tournadre¹, Bruno Pereira², Laure Gossec³, Martin Soubrier⁴ and Maxime Dougados⁵, ¹Rheumatology, UNH-UMR 1019 INRA University of Auvergne and Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ²Biostatistics unit (DRCI), CHU Gabriel Montpied, Clermont-Ferrand, France, ³Sorbonne Universités, UPMC University Paris 06, Paris, France, Paris, France, ⁴Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ⁵Paris-Descartes University, Paris, France
Background/Purpose: The mechanisms of fatigue in rheumatoid arthritis (RA) are still unclear and the effect of antirheumatic drugs on fatigue not fully established. Objectives: To…
Abstract Number: 2061 • 2016 ACR/ARHP Annual Meeting
Successful Treatment of Murine Lupus Nephritis with Helminths Related Tuftsin-Phosphorylcholine Compound and Its Effect on the Microbiota
Yehuda Shoenfeld¹, Tomer Bashi², Hadar Gershon³, Or Givol⁴, Alexander Volkov⁵, Iris Barshack⁵, Mati Fridkin⁶, Miri Blank² and Omry Koren⁷, ¹Zabludowicz Center for Autoimmune Diseases, Chaim Sheba Medical Center, Tel Hashomer, Israel Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel, ²Sheba Medical Center, Zabludowicz Center for Autoimmune Diseases, affiliated to affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Ramat Gan, Israel, ³Sefat Medical School, Bar-Ilan University, Sefat, Israel, ⁴Zabludowicz Center for Autoimmune Diseases, Ramat Gan, Israel, ⁵Sheba Medical Center, Institute of Pathology, affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Ramat Gan, Israel, ⁶Organic chemistry, Weizmann Institute for Sciences, Rehovot, Israel, ⁷Sefat medical school, Bar-Ilan university, Sefat, Israel
Background/Purpose: , In areas where helminths infections are common, autoimmune diseases are rare. Treatment with helminthes and their ova, improved clinical findings of inflammatory bowel…
Abstract Number: 2496 • 2016 ACR/ARHP Annual Meeting
DMARD, Biologic and Small Molecule Drug Use Among ACPA Positive and ACPA Negative RA Patients in a Tertiary Referral Center
Richard Meehan¹, Eric Hoffman², David Muram³, Barbara Goldstein⁴, Jim Crooks⁵ and Pearlanne Zelarney⁶, ¹MEDICINE, National Jewish Health, Denver, CO, ²Medicine/Rheumjatology, National Jewish Health, denver, CO, ³Eli Lilly and Company, Indianapolis, IN, ⁴Rheumatology, National Jewish Health, Denver, CO, ⁵Biostatistics, National Jewish Health, Denver, CO, ⁶Bioinformatics, National Jewish Health, Denver, CO
Background/Purpose: Rheumatoid arthritis (RA) can be divided into two major subsets based on the presence or absence of antibodies to citrullinated peptide antigens (ACPA). Some…
Abstract Number: 52 • 2016 ACR/ARHP Annual Meeting
Pregabalin Dose-Response for Sleep Quality and Pain Response in Fibromyalgia: A Post-Hoc Analysis of Three Randomized Trials
Andrew Clair¹, Ed Whalen¹, Neal Thomas¹ and Lynne Pauer², ¹Pfizer, New York, NY, ²Pfizer, Groton, CT
Background/Purpose: Pregabalin is often administered for treatment of fibromyalgia (FM) at daily doses lower than approved by the US Food and Drug Administration (starting dose…
Abstract Number: 183 • 2016 ACR/ARHP Annual Meeting
Protective Role of Mucosal-Associated Invariant T (MAIT) Cells in an Imiquimod-Induced Psoriasis Model
Goh Murayama¹, Asako Chiba², Hitomi Toda², Ken Yamaji¹, Naoto Tamura³ and Sachiko Miyake⁴, ¹Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Juntendo Univ Sch of Med, Juntendo University School of Medicine, Tokyo, Japan, ³Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ⁴Immunology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Psoriasis is a chronic inflammatory disease of the skin and is often accompanied by arthritis. The underlying pathogenesis of psoriasis is still unclear, but…
Abstract Number: 2103 • 2015 ACR/ARHP Annual Meeting
Temporal Trends in Drug Prescription, Utilization and Costs Among Rheumatoid Arthritis (RA) Patients Show Wide Regional Variation Despite Universal Drug Coverage
Mark Tatangelo¹, Michael Paterson², George A. Tomlinson³, Nick Bansback⁴, Jessica Widdifield⁵, Tara Gomes² and Claire Bombardier⁶, ¹University of Toronto, Toronto, ON, Canada, ²Institute of Clinical Evaluative Sciences, Toronto, ON, Canada, ³Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ⁴Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, ⁵University Health Network, Toronto, ON, Canada, ⁶18 Strathearn Blvd, University of Toronto, Toronto, ON, Canada
Background/Purpose: Monitoring of drug use and costs can: describe trends in expenditures over time, identify regional variations in access and indicate physicians' uptake of best-practice…
Abstract Number: 2425 • 2015 ACR/ARHP Annual Meeting
Safety of Tocilizumab in Young Adults with Juvenile Idiopathic Arthritis (JIA)
Jens Klotsche¹, Martina Niewerth², Johannes Peter Haas³, Angela Zink⁴, Gerd Horneff⁵ and Kirsten Minden⁶, ¹Programme Area Epidemiology, German Rheumatism Research Center, a Leibniz institute, Berlin, Germany, ²Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ³German Centre for Rheumatology in Children and Young People, Garmisch-Partenkirchen, Germany, ⁴Epidemiologie, Deutsches Rheuma-Forschungszentrum, Berlin, Germany, ⁵Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁶Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany
Background/Purpose: Tocilizumab was recently approved for the treatment of systemic JIA (sJIA) and polyarticular JIA (pJIA). Published data on the tolerability of tocilizumab in patients…
Abstract Number: 2694 • 2015 ACR/ARHP Annual Meeting
Variations in the Metabolome in Response to Disease Activity of Rheumatoid Arthritis
Zuzana Tatar¹, Carole Migne², Mélanie Petera³, Estelle Pujos Guillot⁴, Philippe Gaudin^5,6, T Lequerré⁷, Hubert Marotte⁸, Jacques Tebib⁹ and Martin Soubrier¹, ¹Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ²Metabolomic Plateform INRA, Theix-Clermont-Ferrand, France, ³Metabolomic Plateform, INRA, Theix -Clermont-Ferrand, France, ⁴Metabolomic Plateform, INRA, Theix-Clermont-Ferrand, France, ⁵Rheumatology, University Hospital, Grenoble, France, ⁶Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, ⁷Rheumatology Department and INSERM U 905, CHU Hôpitaux de Rouen, Rouen, France, ⁸INSERM 1059 / LBTO, Université de Lyon, Saint-Etienne; Rheumatology Department, Saint-Etienne, France, ⁹Rheumatology Department, Centre Hospitalier Lyon-Sud, Pierre-Bénite Lyon, France
Background/Purpose: Anti-TNF-alpha therapies are able to control rheumatoid arthritis (RA) disease activity and to limit structural damage. Nevertheless, no predictive factor of response to anti-TNF-alpha,…
Abstract Number: 2841 • 2015 ACR/ARHP Annual Meeting
Changes in Treatment Patterns in Psoriatic Arthritis Patients Newly Initiated on Biologic and Non-Biologic Therapy Enrolled in a North American Clinical Registry
Philip J. Mease¹, Tamara Lesperance², Neil Accortt², David Collier², Mei Liu³, Marc Mason⁴ and Sabrina Deveikis⁴, ¹Clinical Professor, University of Washington School of Medicine, Seattle, WA, ²Amgen, Inc., Thousand Oaks, CA, ³352 Turnpike Rd, Corrona, LLC, Southborough, MA, ⁴Corrona, LLC., Southborough, MA
Background/Purpose: Over the past decade, the treatment of PsA has improved significantly. The purpose of this study was to describe real-world treatment patterns among PsA…
Abstract Number: 2926 • 2015 ACR/ARHP Annual Meeting
Cytochrome P450 Polymorphisms on Blood Hydroxychloroquine Levels in Patients with Systemic Lupus Erythematosus
Ji Yeon Lee¹, Min Kyung Chung², Ji Hun Kim², Jung Hee Koh³, Seung Min Jung⁴, Jennifer Lee², Seung-Ki Kwok⁵, Ji Hyeon Ju⁶, Kyung-Su Park⁷ and Sung-Hwan Park², ¹Division of Rheumatology, Department of Internal Medicine, School of Medicine, Catholic University of Korea, Seoul St. Mary’s Hospital, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, school of medicine, The catholic university of Korea, Seoul, South Korea, ⁵[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁷Division of Rheumatology, Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Hydroxychloroquine (HCQ) is a safe and effective treatment for systemic lupus erythematosus (SLE), and its blood concentration is known to be closely related to…
Abstract Number: 2380 • 2014 ACR/ARHP Annual Meeting
Durability of First Biologic Is Not Influenced By Initial/Early DAS28
Gina Rohekar¹, Binu Jacob², Janet E. Pope³ and Claire Bombardier⁴, ¹Rheumatology, St. Joseph's Hospital, London, ON, Canada, ²University Health Network, Toronto General Research Institute, Toronto, ON, Canada, ³Medicine, Western University, London, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: The Ontario Best Practices Research Initiative (OBRI) collects data on RA treatment in a real-world setting. Patients are enrolled and prospectively followed to…
Abstract Number: 1879 • 2014 ACR/ARHP Annual Meeting
The Efficacy of Pregabalin for Treating Fibromyalgia Patients with Moderate or Severe Baseline Widespread Pain
Andrew Clair and Birol Emir, Pfizer Inc, New York, NY
Background/Purpose: Pregabalin has demonstrated efficacy for the treatment of fibromyalgia (FM), but insufficient evidence exists on how the efficacy of pregabalin may differ by baseline…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].